Join our daily newsletter At The Bell to receive exclusive market insights
- Proteomics International Laboratories (PIQ) sees its cash reserves strengthened by a $1.2 million research and development tax incentive for the 2020/2021 financial year
- During FY21 Proteomics spent $2.85 million on R&D, enabling the company to receive an Australian Government rebate of 43.5 per cent
- Proteomics says it has been working to pursue ground-breaking R&D with blue-sky potential in next generation diagnostic tests, including the commercialisation of its predictive test for diabetic kidney disease
- The company says it will continue to invest in its biomarker discovery program centered on the Promarker technology platform
- Proteomics last traded at $1.13 on December 13
Proteomics International Laboratories (PIQ) has seen its cash reserves strengthened by the receipt of a $1.2 million research and development tax incentive for the 2020/2021 financial year.
Over the past financial year Proteomics spent $2.85 million on research and development (R&D), enabling the company to receive an Australian Government rebate of $1,24 million.
The Federal R&D tax incentive encourages companies engaging in research considered beneficial to Australia by offering a cash rebate of 43.5 per cent for qualifying activities.
Proteomics said it has been working to pursue ground-breaking R&D with blue-sky potential in next generation diagnostic tests.
Commercialisation for PromarkerD, the company’s predictive test for diabetic kidney disease, has been ongoing, along with developing new fee-for-service analytical methods.
PromarkerD is a prognostic test that can predict future kidney decline in patients with either type 2 diabetes or no existing diabetic kidney disease, using a simple blood test that measures three serum protein biomarkers.
Study results have shown PromarkerD can outperformed the current tests used to predicting the onset of diabetic kidney disease during a four-year follow-up period.
The company says it will continue to invest in its biomarker discovery program centred on the Promarker technology platform.
Proteomics last traded at $1.13 on December 13.
